EGFR and non-small cell lung carcinoma: In EGFR-mutated NSCLC treated with EGFR-TKIs, the underlying mechanism of its adaptive resistance is largely a secondary EGFR mutation that causes amino acid substitutions, such as T790M and C797S, in an intrinsic kinase domain [11,12].